Drug Co. Misrepresented Products' FDA Status, SEC Says

Law360, New York (December 14, 2012, 7:16 PM EST) -- The U.S. Securities and Exchange Commission hit BioChemics Inc. with a lawsuit Friday in Massachusetts federal court, accusing the biopharmaceutical company of selling investors $9 million worth of stock by falsely suggesting that its products would soon secure the necessary regulatory approvals.

The SEC accuses BioChemics of misleading 70 investors from 19 states about the status of its products — gels that allow drugs to be delivered into the bloodstream through the skin — with the U.S. Food & Drug Administration, which had neither approved the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Securities and Exchange Commission v. Biochemics, Inc et al


Case Number

1:12-cv-12324

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Mark L. Wolf

Date Filed

December 14, 2012

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.